United Therapeutics Corporation announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In… read more.
New data from Eli Lilly and Company showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patients with moderately to severely active ulcerative colitis (UC)… read more.
Gilead Sciences, Inc. and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at the European Society for… read more.
Inspire Medical Systems Inc. published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company’s limited market release in the United States including… read more.
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Annual Meeting,… read more.
Jascayd (nerandomilast) tablets has been approved by the FDA as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients. Jascayd is the first and only… read more.
AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October… read more.
Medtronic announced the results from the Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial now published in the distinguished Journal of the American Medical… read more.
Roche announced that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21… read more.
Johnson & Johnson announced new 48-week data from the Phase III ASTRO study evaluating Tremfya (guselkumab) subcutaneous (SC) induction and maintenance therapy in adults with moderately to severely… read more.
Regeneron Pharmaceuticals, Inc. announced that the FDA has approved Evkeeza (evinacumab-dgnb) ANGPTL3 antibody as an adjunct to diet and exercise and other lipid-lowering therapies for the treatment of… read more.
At the European Society for Medical Oncology (ESMO) Congress 2025, Boehringer Ingelheim will present new data from across its robust oncology pipeline, including non-small cell lung cancer (NSCLC)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
